1. Anti-pseudo-PCNA type 1 (anti-SG2NA) pattern: Track down Cancer, not SLE
- Author
-
Emmanuel Andrès, Alina Dima, Benoit Nespola, Joëlle Goetz, Jérôme De Seze, François Habersetzer, Patrick Ohlmann, Jean-Louis Pasquali, Anne-Sophie Korganow, Bernard Cribier, Vincent Poindron, Raoul Herbrecht, Aurélien Guffroy, Elisabeth Quoix, Thierry Martin, Bruno Langer, Jean Sibilia, Immunopathologie et chimie thérapeutique (ICT), Institut de biologie moléculaire et cellulaire (IBMC), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques (BMNST), Institut de Recherche sur les Maladies Virales et Hépatiques (IVH), Biotechnologie et signalisation cellulaire (BSC), and Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Institut de recherche de l'Ecole de biotechnologie de Strasbourg (IREBS)
- Subjects
0301 basic medicine ,Adult ,Anti-nuclear antibody ,Indirect immunofluorescence assay ,Lupus ,Cell Cycle Proteins ,Disease ,Autoantigens ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,Neoplasms ,Proliferating Cell Nuclear Antigen ,medicine ,Humans ,Lupus Erythematosus, Systemic ,Clinical significance ,B cell ,Autoantibodies ,Cancer ,Aged ,Retrospective Studies ,030203 arthritis & rheumatology ,Systemic lupus erythematosus ,biology ,business.industry ,Autoantibody ,Middle Aged ,medicine.disease ,SG2NA protein ,3. Good health ,030104 developmental biology ,medicine.anatomical_structure ,Antibodies, Antinuclear ,Immunology ,biology.protein ,Calmodulin-Binding Proteins ,Antibody ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
OBJECTIVE Describe the clinical significance of anti-SG2NA antibodies also called anti-pseudo-PCNA type 1 (proliferating cell nuclear antigen auto-antibodies) which are rare antinuclear antibodies (ANAs) staining distinctly S/G2 proliferative HEp-2 cells by indirect immunofluorescence. By analogy with anti-PCNA antibodies, they have been suspected to be associated with systemic lupus erythematosus (SLE), cancers or viral diseases. METHODS From May 2006 to February 2013, 16,827 patients were tested positive for ANAs in the Laboratory of Immunology, Strasbourg, France. We retrospectively analyzed clinical and biological data from 126 patients with anti-pseudo-PCNA type 1 antibodies. RESULTS There was a 0.75% prevalence of anti-pseudo-PCNA type 1 Abs among ANAs(+) patients. Median age was 56.9 years (standard deviation [SD] 13.4 years) with a sex ratio female/male of 1.9. Compared to ANAs(+) patients, many more patients have been hospitalized in the Oncology and Hematology Department (23% vs. 6.3%, P
- Published
- 2015